RECRUITING

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.

Official Title

Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes

Quick Facts

Study Start:2019-10-10
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05973799

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * males and females of any race or ethnicity
  2. * non-obese (BMI \< or = to 30)
  3. * have a diagnosis of type 1 diabetes
  4. * C-peptide negative
  1. * pregnant women
  2. * cigarette smoking
  3. * Taking inflammation-targeting steroids (e.g., prednisone).
  4. * Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
  5. * Hematocrit less than 33%.
  6. * Presence of HIV or hepatitis (due to their deleterious effects on the liver).
  7. * The presence of cardiovascular or peripheral vascular disease.
  8. * The presence of neuropathy, retinopathy or nephropathy.
  9. * A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.

Contacts and Locations

Study Contact

Jason Winnick, PhD
CONTACT
513-558-4437
jason.winnick@uc.edu
Alyssa Randolph
CONTACT
513-558-3427
Randolas@ucmail.uc.edu

Study Locations (Sites)

University of Cincinnati
Cincinnati, Ohio, 45267-0547
United States

Collaborators and Investigators

Sponsor: University of Cincinnati

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-10-10
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2019-10-10
Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

  • glucagon
  • hepatic glucose metabolism
  • liver glycogen

Additional Relevant MeSH Terms

  • Hypoglycemia
  • Type1diabetes